Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific Officer

  Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific
  Officer

Dr. Olson’s Extensive Experience in Personalized Medicine Will Support Syros’
                       Mission to Lead in Gene Control

Business Wire

WATERTOWN, Mass. -- May 22, 2013

Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in
gene control to revolutionize the treatment of cancer and other diseases,
announced today that Eric R. Olson, Ph.D., has joined the company as its Chief
Scientific Officer. Dr. Olson has over 25 years experience in the life
sciences industry, most recently as Research Vice President for respiratory
diseases at Vertex Pharmaceuticals. During his 12 years at Vertex he led
research, development and commercial teams in bringing to patients the first
cystic fibrosis (CF) treatment resulting from discovery of the CF gene.

“Eric is of the few people in the biopharma industry who have led programs
from conception all the way through development and successful
commercialization,” said Nancy Simonian, M.D., Syros’s Chief Executive
Officer. “The combination of his deep scientific expertise, his understanding
for translating science into drugs that actually help people, and his
experience creating real value for shareholders is extraordinary. It fits
perfectly with Syros' mission.”

In addition to his work at Vertex Pharmaceuticals, Dr. Olson has also held
positions as the Director of the Antibacterials and Molecular Sciences
departments at Warner-Lambert (now Pfizer), as well as a research scientist
focused on gene expression systems with The Upjohn Company. Dr. Olson earned
his B.S. in microbiology from the University of Minnesota and a Ph.D. in
microbiology and immunology from the University of Michigan. He is published
in over 40 academic journals.

“Syros Pharmaceuticals’ groundbreaking work in gene control and
Super-Enhancers has created a unique, state-of-the-art opportunity to develop
novel medicines focused on disease dependency genes,” said Dr. Olson. “I am
excited to lead the scientific efforts at a company conducting this type of
innovative research, and look forward to working with Syros’ experienced
management team and renowned scientific advisory board to develop new
breakthrough therapies.”

About Syros Pharmaceuticals

Syros Pharmaceuticals is a life sciences company harnessing breakthroughs in
gene control to revolutionize the treatment of cancer and other diseases.
Syros’ proprietary platform identifies the master switches for disease genes,
opening a whole new approach to novel therapeutics. Syros’ initial focus is in
cancer, but the company platform will also be applicable to other therapeutic
areas. The Company’s founders are pioneers in gene control research and
translation. Co-founded and backed by Flagship Ventures and ARCH Venture
Partners, Syros Pharmaceuticals is located in Watertown, MA. For more
information, visit www.syros.com.

Contact:

Sam Brown Inc.
Mike Beyer, 312-961-2502
beyer@sambrown.com
 
Press spacebar to pause and continue. Press esc to stop.